Literature DB >> 20011569

Accomplishments in 2008 in the management of gastrointestinal stromal tumors.

Daniel Renouf1, Jean-Yves Blay, Charles Blanke.   

Abstract

Overview of the Disease ProcessIncidencePrognosisPredictive MarkersCurrent General Therapy Standards in North America and EuropeLocalized or Potentially Resectable DiseaseUnresectable or Metastatic DiseaseAccomplishments During the YearTherapySurgical Issues and Perioperative TherapyImatinibSunitinibNew DrugsBiomarkersBasic and Other Translational ScienceWhat Needs to Be DoneFuture DirectionsComments on ResearchObstacles to Progress.

Entities:  

Year:  2009        PMID： 20011569      PMCID： PMC2791388     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  37 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors:  George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

3.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

4.  A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Authors:  Jonathan C Trent; Jennifer Beach; Michael A Burgess; Nicholas Papadopolous; Lei L Chen; Robert S Benjamin; Shreyaskumar R Patel
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

5.  Molecular characterization of pediatric gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Michael P Laquaglia; Berrin Ustun; Tianhua Guo; Grace C Wong; Nicholas D Socci; Robert G Maki; Ronald P DeMatteo; Peter Besmer; Cristina R Antonescu
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

6.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

Authors:  Heikki Joensuu
Journal:  Hum Pathol       Date:  2008-10       Impact factor: 3.466

7.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

8.  Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Authors:  John H Edmonson; Randolph S Marks; Jan C Buckner; Michelle R Mahoney
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

9.  Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.

Authors:  P Blume-Jensen; L Claesson-Welsh; A Siegbahn; K M Zsebo; B Westermark; C H Heldin
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

Authors:  John C McAuliffe; Kelly K Hunt; Alexander J F Lazar; Haesun Choi; Wei Qiao; Peter Thall; Raphael E Pollock; Robert S Benjamin; Jonathan C Trent
Journal:  Ann Surg Oncol       Date:  2008-10-25       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.